Steve Schonfeld Schonfeld Strategic Advisors
Steve Schonfeld is the founder of Schonfeld Strategic Advisors, a multi-manager investment firm with roots in proprietary trading. Schonfeld allocates capital across quantitative and discretionary strategies with an emphasis on risk controls and diversification of return streams. The firm is a major name in the multi-strategy hedge fund landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$5.4B |
| 2 |
NVIDIA
NVDA
|
+$388M |
| 3 |
Microsoft
MSFT
|
+$182M |
| 4 |
Amazon
AMZN
|
+$177M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$163M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$213M |
| 2 |
Broadcom
AVGO
|
+$103M |
| 3 |
Union Pacific
UNP
|
+$100M |
| 4 |
ETHA
iShares Ethereum Trust ETF
ETHA
|
+$89.9M |
| 5 |
Marvell Technology
MRVL
|
+$89.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.68% |
| 2 | Industrials | 8.46% |
| 3 | Financials | 6.55% |
| 4 | Consumer Discretionary | 5.99% |
| 5 | Healthcare | 5.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Independence Realty Trust
IRT
$3.98B
| $2.42M | 0.01% |
138,632
-1,019,284
| -88% | -$16.9M |
|
802
PUT
C.H. Robinson
CHRW
$16.7B
| $2.41M | 0.01% |
+15,000
| New | +$2.22M |
|
|
LTC
803
LTC Properties
LTC
$2.18B
| $2.4M | 0.01% |
69,862
+32,997
| +90% | +$1.16M |
|
804
Nomad Foods
NOMD
$1.69B
| $2.4M | 0.01% |
191,858
+150,864
| +368% | +$1.84M |
|
805
Philips
PHG
$26.9B
| $2.39M | 0.01% |
91,563
+82,512
| +912% | +$2.2M |
|
|
CBC
806
Central Bancompany Inc
CBC
$7.77B
| $2.39M | 0.01% |
+99,051
| New | +$2.33M |
|
807
Baidu
BIDU
$31.3B
| $2.39M | 0.01% |
18,280
+16,229
| +791% | +$2.01M |
|
|
CADE
808
DELISTED
Cadence Bank
CADE
| $2.39M | 0.01% |
55,675
+42,193
| +313% | +$1.67M |
|
809
Public Service Enterprise Group
PEG
$36.6B
| $2.38M | 0.01% |
29,687
-24,901
| -46% | -$2.03M |
|
|
DRDB
810
Roman DBDR Acquisition Corp II
DRDB
$326M
| $2.38M | 0.01% |
228,293
-1,307
| -0.6% | -$13.6K |
|
811
Viking Therapeutics
VKTX
$3.88B
| $2.38M | 0.01% |
67,647
-176,812
| -72% | -$6.26M |
|
812
AvePoint
AVPT
$2.8B
| $2.37M | 0.01% |
170,661
+156,083
| +1,071% | +$2.16M |
|
|
DRUG
813
Bright Minds Biosciences
DRUG
$756M
| $2.36M | 0.01% |
30,211
-36,395
| -55% | -$2.43M |
|
814
Red Rock Resorts
RRR
$3.59B
| $2.35M | 0.01% |
37,940
-69,568
| -65% | -$4.07M |
|
|
INGM
815
Ingram Micro Holding
INGM
$6.41B
| $2.33M | 0.01% |
109,338
+24,133
| +28% | +$523K |
|
816
Morningstar
MORN
$8.16B
| $2.33M | 0.01% |
10,712
-13,533
| -56% | -$2.93M |
|
817
Arcus Biosciences
RCUS
$3.84B
| $2.32M | 0.01% |
97,283
+48,389
| +99% | +$987K |
|
|
BCAR
818
D. Boral ARC Acquisition I Corp
BCAR
$228M
| $2.31M | 0.01% |
230,000
-27,631
| -11% | -$277K |
|
819
Global Net Lease
GNL
$2.13B
| $2.3M | 0.01% |
267,822
+25,114
| +10% | +$201K |
|
820
Inspire Medical Systems
INSP
$1.78B
| $2.3M | 0.01% |
24,947
+19,794
| +384% | +$1.89M |
|
821
Royal Caribbean
RCL
$78.4B
| $2.3M | 0.01% |
+8,235
| New | +$2.33M |
|
822
C3.ai
AI
$1.57B
| $2.29M | 0.01% |
169,880
-7,633
| -4% | -$122K |
|
823
AES
AES
$10.5B
| $2.29M | 0.01% |
159,355
+41,304
| +35% | +$582K |
|
824
Oscar Health
OSCR
$9.82B
| $2.28M | 0.01% |
+158,833
| New | +$2.75M |
|
825
RxSight
RXST
$260M
| $2.28M | 0.01% |
218,675
-338,926
| -61% | -$3.4M |
|
Similar funds
Steve Schonfeld's Q4 2025 Portfolio in Review
As of Q4 2025, Steve Schonfeld held 2,774 positions worth $22.6B, up 28% from $17.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Steve Schonfeld deployed $4.53B of net new capital in Q4 2025, opening 620 new positions and adding to 589 existing holdings. Its largest new stake was Medline Inc: 1,945,050 shares worth $81.7M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 14% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $213M trimmed.
- Steve Schonfeld's largest Q4 2025 buy was Medline Inc: 1,945,050 shares worth $81.7M.
- Steve Schonfeld added most to iShares Core S&P 500 ETF in Q4 2025, an estimated $5.4B increase.
- Steve Schonfeld's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $213M.
- Steve Schonfeld fully exited Southwest Airlines in Q4 2025, selling an estimated $73.9M.
- Steve Schonfeld's ten largest holdings make up 41% of its $22.6B portfolio in Q4 2025.
- Steve Schonfeld opened 620 new positions and closed 789 in Q4 2025.
- Steve Schonfeld's portfolio value rose 28% quarter-over-quarter to $22.6B.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.